Potential New 2nd line Therapy for PBC

Seladelpar (CymaBay) may replace obeticholic acid as a second line therapy for PBC. About 40% of patient with PBC may not respond to Ursodeoxycholic acid (UDCA) which is the current first line therapy. Similarly, half of patient's fail to respond to obeticholic acid.

0 views0 comments

Recent Posts

See All

Makipour and Modiri Gastroenterology 

2280 Opitz Blvd, suite #200

Woodbridge, VA, 22191

gi specialist

  • Twitter Social Icon
  • Facebook Basic Black
  • Google+ Basic Black

Copyright drmakipour, Houshang Makpour MD 2017, Powered by Wix